Ajanta Pharma Receives US FDA Clearance for Dahej Facility
Ajanta Pharma, a prominent pharmaceutical company, has recently obtained clearance from the United States Food and Drug Administration (US FDA) for its Dahej facility following a comprehensive inspection. Notably, no Form 483, which signifies non-compliance issues, was issued by the regulatory authority after completing its audit of Ajanta Pharma’s Dahej facility on June 23. The US FDA audit, carried out by officials from June 19 to June 23, 2023, has been confirmed by the pharmaceutical company through its official stock filing.
Following the news of US FDA clearance, the company experienced a positive boost in its stock price, with an increase of nearly 4 percent during early trade. As of 10:38 am, shares were trading up by 2.95% at ₹1503.85 apiece on the Bombay Stock Exchange (BSE). The stock opened at ₹1504.95 apiece, contributing to a market capitalization of ₹18,935.83 crore on the BSE.
Ajanta Pharma promptly communicated the development to its stakeholders, stating, “This is to inform you that our formulation facility at Dahej was inspected by the US FDA from June 19 to June 23, 2023. No Form 483 was issued to us at the conclusion of the inspection,” as mentioned in their stock filing.
Also Read: IdeaForge Tech IPO: Fully Booked on Day 1; Details Inside
Closing at ₹1461.60 apiece on the BSE, Ajanta Pharma’s stock experienced a decline of 3.26% on Friday. It is worth noting that the stock reached its 52-week high on June 22, trading at ₹1,550 apiece on the BSE.
About Ajanta Pharma:
Ajanta Pharma Engineers is renowned for its exceptional precision and accuracy in manufacturing Strip Packing Machines. In addition to Strip Packing, we have expanded our expertise to include the production of Blister Packing Machines and ALU ALU Blister Packing Machines, making a remarkable entry into the market.
For more of the Latest News, Click Here
